The use of subcutaneous golimumab, a fully human anti-TNFα* monoclonal antibody, resulted in significant improvement in clinical responses in children with active polyarticular course of juvenile idiopathic arthritis (polyJIA), according to the GO KIDS** trial.
Interleukin (IL)-18 inhibition using the recombinant human IL-18 binding protein tadekinig alfa demonstrated early signs of efficacy and a favourable safety profile in patients with adult-onset Still’s disease (AOSD), a rare inflammatory disease of unknown aetiology, a phase II study shows.
The addition of the antirheumatic agent hydroxychloroquine to a regular pain regimen does not provide clinically-relevant pain relief for patients with moderate-to-severe hand osteoarthritis, according to the HERO* trial.
Tai chi mind-body treatment appears to deliver similar or greater improvement in symptoms for a variety of outcomes for patients with fibromyalgia than aerobic exercise, the current most commonly prescribed nondrug treatment, according to a new study.
Continued treatment with the anti-interleukin (IL)-23 monoclonal antibody guselkumab generated high efficacy response rates in patients with moderate-to-severe plaque psoriasis, according to findings from the ongoing phase III VOYAGE 2* trial presented at the 2018 American Academy of Dermatology Annual Meeting (AAD 2018) held in San Diego, California, US.
Long-term use of febuxostat, a nonpurine xanthine oxidase inhibitor, was associated with higher all-cause and cardiovascular (CV) deaths despite noninferiority to allopurinol in terms of adverse CV events, findings from the CARES* trial showed. This finding raises safety issues regarding the treatment of gout in patients with major CV disease.
Initial response to therapy plays a predictive role in psoriatic arthritis, such that disease activity levels 3 months after treatment initiation may be used to evaluate the potential for achieving therapeutic targets at later time points, as reported in a recent study.
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Abnormalities on ultrasound (US) examination may predict relapse in juvenile idiopathic arthritis (JIA) at the individual level, with a recent study showing that signs of inflammation on US are associated with about a fourfold increase in the risk of flare.
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.